Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Fernández de Henestrosa AR"'
Publikováno v:
Moleculargeneral genetics : MGG. 245(4)
The recA genes of Agrobacterium tumefaciens, Rhizobium meliloti, Rhizobium phaseoli and Rhodobacter sphaeroides, species belonging to the alpha-group bacteria of the Proteobacteria class, have been fused in vitro to the lacZ gene of Escherichia coli.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df10730c39b32a0658ce24b56c72d871
https://pubmed.ncbi.nlm.nih.gov/7808403
https://pubmed.ncbi.nlm.nih.gov/7808403
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Guzmán A; Toxicology Department, Welab Barcelona and Toxicology Department Esteve Pharmaceuticals, Spain. Electronic address: aguzman@welab.barcelona., Encina G; Development PK & Bioanalysis Department WeLab Barcelona and Development PK & Bioanalysis Department, Esteve Pharmaceuticals, Spain., Fernández de Henestrosa AR; Toxicology Department, Welab Barcelona and Toxicology Department Esteve Pharmaceuticals, Spain., Vila C; Toxicology Department, Welab Barcelona and Toxicology Department Esteve Pharmaceuticals, Spain., Tortajada A; Toxicology Department, Welab Barcelona and Toxicology Department Esteve Pharmaceuticals, Spain., Marín AP; Toxicology Department, Welab Barcelona and Toxicology Department Esteve Pharmaceuticals, Spain.
Publikováno v:
Regulatory toxicology and pharmacology : RTP [Regul Toxicol Pharmacol] 2021 Jun; Vol. 122, pp. 104916. Date of Electronic Publication: 2021 Mar 09.
Autor:
Fernández de Henestrosa AR; Department of Toxicology, ESTEVE Pharamaceuticals, Barcelona and Department of Toxicology, WELAB, Barcelona, Spain., Marín AP; Department of Toxicology, ESTEVE Pharamaceuticals, Barcelona and Department of Toxicology, WELAB, Barcelona, Spain., Tortajada A; Department of Toxicology, ESTEVE Pharamaceuticals, Barcelona and Department of Toxicology, WELAB, Barcelona, Spain., Vila C; Department of Toxicology, ESTEVE Pharamaceuticals, Barcelona and Department of Toxicology, WELAB, Barcelona, Spain., Guzmán A; Department of Toxicology, ESTEVE Pharamaceuticals, Barcelona and Department of Toxicology, WELAB, Barcelona, Spain.
Publikováno v:
Drug research [Drug Res (Stuttg)] 2021 Feb; Vol. 71 (2), pp. 73-82. Date of Electronic Publication: 2020 Nov 04.
Autor:
García M; ESTEVE Pharmaceuticals S.A., Torre Esteve, Passeig de la Zona Franca, 109, 08038 Barcelona, Spain.; WELAB, Parc Científic Barcelona, C/Baldiri Reixac 4-8, 08028 Barcelona, Spain., Virgili M; Enantia, S.L., Carrer Baldiri Reixac, 10, Parc Científic de Barcelona, 08028 Barcelona, Spain., Alonso M; Enantia, S.L., Carrer Baldiri Reixac, 10, Parc Científic de Barcelona, 08028 Barcelona, Spain., Alegret C; Enantia, S.L., Carrer Baldiri Reixac, 10, Parc Científic de Barcelona, 08028 Barcelona, Spain., Farran J; Enantia, S.L., Carrer Baldiri Reixac, 10, Parc Científic de Barcelona, 08028 Barcelona, Spain., Fernández B; ESTEVE Pharmaceuticals S.A., Torre Esteve, Passeig de la Zona Franca, 109, 08038 Barcelona, Spain.; WELAB, Parc Científic Barcelona, C/Baldiri Reixac 4-8, 08028 Barcelona, Spain., Bordas M; ESTEVE Pharmaceuticals S.A., Torre Esteve, Passeig de la Zona Franca, 109, 08038 Barcelona, Spain.; WELAB, Parc Científic Barcelona, C/Baldiri Reixac 4-8, 08028 Barcelona, Spain., Pascual R; ESTEVE Pharmaceuticals S.A., Torre Esteve, Passeig de la Zona Franca, 109, 08038 Barcelona, Spain.; WELAB, Parc Científic Barcelona, C/Baldiri Reixac 4-8, 08028 Barcelona, Spain., Burgueño J; ESTEVE Pharmaceuticals S.A., Torre Esteve, Passeig de la Zona Franca, 109, 08038 Barcelona, Spain.; WELAB, Parc Científic Barcelona, C/Baldiri Reixac 4-8, 08028 Barcelona, Spain., Vidal-Torres A; ESTEVE Pharmaceuticals S.A., Torre Esteve, Passeig de la Zona Franca, 109, 08038 Barcelona, Spain.; WELAB, Parc Científic Barcelona, C/Baldiri Reixac 4-8, 08028 Barcelona, Spain., Fernández de Henestrosa AR; ESTEVE Pharmaceuticals S.A., Torre Esteve, Passeig de la Zona Franca, 109, 08038 Barcelona, Spain.; WELAB, Parc Científic Barcelona, C/Baldiri Reixac 4-8, 08028 Barcelona, Spain., Ayet E; ESTEVE Pharmaceuticals S.A., Torre Esteve, Passeig de la Zona Franca, 109, 08038 Barcelona, Spain.; WELAB, Parc Científic Barcelona, C/Baldiri Reixac 4-8, 08028 Barcelona, Spain., Merlos M; ESTEVE Pharmaceuticals S.A., Torre Esteve, Passeig de la Zona Franca, 109, 08038 Barcelona, Spain.; WELAB, Parc Científic Barcelona, C/Baldiri Reixac 4-8, 08028 Barcelona, Spain., Vela JM; ESTEVE Pharmaceuticals S.A., Torre Esteve, Passeig de la Zona Franca, 109, 08038 Barcelona, Spain.; WELAB, Parc Científic Barcelona, C/Baldiri Reixac 4-8, 08028 Barcelona, Spain., Plata-Salamán CR; ESTEVE Pharmaceuticals S.A., Torre Esteve, Passeig de la Zona Franca, 109, 08038 Barcelona, Spain., Almansa C; ESTEVE Pharmaceuticals S.A., Torre Esteve, Passeig de la Zona Franca, 109, 08038 Barcelona, Spain.; WELAB, Parc Científic Barcelona, C/Baldiri Reixac 4-8, 08028 Barcelona, Spain.
Publikováno v:
Journal of medicinal chemistry [J Med Chem] 2020 Dec 24; Vol. 63 (24), pp. 15508-15526. Date of Electronic Publication: 2020 Oct 16.
Autor:
Bolt MW; Pfizer, Drug Safety Research and Development, Cambridge, MA 02139, USA., Whiteley LO; Pfizer, Drug Safety Research and Development, Cambridge, MA 02139, USA., Lynch JL; Jansen Research and Development, LLC, Nonclinical Safety, Spring House, PA 19477, USA., Lauritzen B; Novo Nordisk A/S, Global Discovery and Development Sciences, 2760 Maaloev, Denmark., Fernández de Henestrosa AR; ESTEVE Pharmaceuticals, Department of Toxicology, 08028 Barcelona, Spain., MacLachlan T; Novartis Institutes for Biomedical Research, Department of Preclinical Safety, Cambridge, MA 02139, USA., Ulrich P; Novartis Institutes for Biomedical Research, Safety Assessment Group, 4002 Basel, Switzerland., Philip BK; Abbvie Preclinical Safety, North Chicago, IL 60064, USA., Mahalingaiah PK; Abbvie Preclinical Safety, North Chicago, IL 60064, USA., Fuller CL; Merck and Co., Safety Assessment and Laboratory Animal Resources, West Point, PA 19486, USA., Compton DR; Sanofi US, Preclinical Safety Development Projects, Bridgewater, NJ 08807, USA.
Publikováno v:
Molecular therapy. Methods & clinical development [Mol Ther Methods Clin Dev] 2020 Sep 01; Vol. 19, pp. 89-98. Date of Electronic Publication: 2020 Sep 01 (Print Publication: 2020).
Autor:
Díaz JL; Drug Discovery and Preclinical Development, Esteve, Baldiri Reixach 4-8, 08028 Barcelona, Spain. jldiaz@esteve.es, Christmann U, Fernández A, Luengo M, Bordas M, Enrech R, Carro M, Pascual R, Burgueño J, Merlos M, Benet-Buchholz J, Cerón-Bertran J, Ramírez J, Reinoso RF, Fernández de Henestrosa AR, Vela JM, Almansa C
Publikováno v:
Journal of medicinal chemistry [J Med Chem] 2013 May 09; Vol. 56 (9), pp. 3656-65. Date of Electronic Publication: 2013 Apr 26.
Autor:
Guzmán A; Toxicology Department, ESTEVE, Mare de Déu de Montserrat 221, 08041, Barcelona, Spain. aguzman@esteve.es, Marín AP, García C, Fernández de Henestrosa AR, Ruiz MT, Tortajada A, Marcos R
Publikováno v:
Environmental and molecular mutagenesis [Environ Mol Mutagen] 2008 Dec; Vol. 49 (9), pp. 727-33.
Autor:
Guzmán A; Toxicology Department, ESTEVE, Mare de Déu de Montserrat 221, 08041 Barcelona, Spain. aguzman@esteve.es, García C, Marín AP, Tortajada A, Ruiz MT, Fernández de Henestrosa AR, Marcos R
Publikováno v:
Mutation research [Mutat Res] 2008 Oct 30; Vol. 656 (1-2), pp. 8-13. Date of Electronic Publication: 2008 Jul 30.
Autor:
Guzmán A; Toxicology Department, ESTEVE, Mare de Deu de Montserrat 221, 08041 Barcelona, Spain. aguzman@esteve.es, García C, Marín AP, Proudlock RJ, Fernández de Henestrosa AR, Ruiz MT, Tortajada A, Lloyd M, Marcos R
Publikováno v:
Mutation research [Mutat Res] 2008 May 31; Vol. 653 (1-2), pp. 91-8. Date of Electronic Publication: 2008 Apr 16.